Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical development of IDH1 inhibitors for cancer therapy.

Cancer treatment reviews - 1 Feb 2022

Zarei Mehrdad, Hue Jonathan J, Hajihassani Omid, Graor Hallie J, Katayama Erryk S, Loftus Alexander W, Bajor David, Rothermel Luke D, Vaziri-Gohar Ali, Winter Jordan M

Abstract excerpt

Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). With only one phase III trial published to date and two indications approved for routine clinical use by the FDA, we reviewed the entire clinical trial portfolio to broadly understand mtIDH1 inhibitor activity in patients. We queried PubMed.gov and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Clinical Trials as Topic

Share to Enzyme Inhibitors

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Pyridines

Source

Identifiers

PMID: 34974243
DOI: 10.1016/j.ctrv.2021.102334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical development of IDH1 inhibitors for cancer therapy.PMID 34974243Read ↗

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To DateSemantic proximity Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Ivosidenib: First Global ApprovalSemantic proximity Read ↗

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Semantic proximity Read ↗

Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database.Semantic proximity Read ↗

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib: A Review in Advanced Cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.